Oncopeptides AB (ONCO) — Cash Flow-to-Debt Ratio
Oncopeptides AB (ONCO) has a Cash Flow-to-Debt Ratio of -1.12x as of December 2025, meaning its operating cash flow of Skr-216.49 Million could theoretically repay -1% of its total liabilities (Skr193.73 Million) in one year. Explore Oncopeptides AB long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Oncopeptides AB Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Oncopeptides AB across 12 annual periods. Also explore ONCO asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Oncopeptides AB (2014–2025)
Year-by-year debt coverage analysis for Oncopeptides AB. For market capitalisation and broader financial context, see Oncopeptides AB stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.15x | Skr-222.88 Million | Skr193.73 Million | ▲ +16.2% |
| 2024 | -1.37x | Skr-260.57 Million | Skr189.91 Million | ▲ +10.8% |
| 2023 | -1.54x | Skr-279.49 Million | Skr181.60 Million | ▲ +66.7% |
| 2022 | -4.62x | Skr-420.51 Million | Skr91.03 Million | ▲ +30.4% |
| 2021 | -6.64x | Skr-1.52 Billion | Skr228.51 Million | ▼ -89.3% |
| 2020 | -3.51x | Skr-1.30 Billion | Skr369.86 Million | ▲ +0.3% |
| 2019 | -3.51x | Skr-690.57 Million | Skr196.47 Million | ▼ -35.5% |
| 2018 | -2.59x | Skr-333.73 Million | Skr128.70 Million | ▲ +41.0% |
| 2017 | -4.39x | Skr-271.50 Million | Skr61.82 Million | ▼ -23.4% |
| 2016 | -3.56x | Skr-104.26 Million | Skr29.30 Million | ▲ +52.8% |
| 2015 | -7.54x | Skr-52.81 Million | Skr7.00 Million | ▼ -32.4% |
| 2014 | -5.70x | Skr-31.44 Million | Skr5.52 Million | — |